Project Grant R21NS132006
Award Date
9/25/23
Completion Date
8/31/25
Dollars Obligated
$424K
Federal Agency
National Institute of Neurological Disorders and Stroke
Federal Grant Program
93.853
Assistance Type
Project Grant
Place of Performance
Detroit, MI 48201, USA
Similar Awards
This $624,583 federal Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, will support research to identify new therapeutic targets for ischemic stroke prevention. The University of Washington, as the primary awardee, will leverage previously collected plasma samples, genomic data, and electronic medical record data from participants in the Heart...
The National Institute of Neurological Disorders and Stroke (NINDS) awarded a $423,500 Project Grant (CFDA 93.853 - Extramural Research Programs in the Neurosciences and Neurological Disorders) to the Augusta University Research Institute, Inc. The objective is to develop and evaluate engineered exosomes carrying neuron-targeting peptides and a therapeutic protein (neuroglobin) for treating ischemic stroke. The research will: 1) characterize the engineered exosomes and assess their...
This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, is focused on evaluating a novel biopharmaceutical agent called Sanguinate for mitigating cerebral infarct growth in acute ischemic stroke. The $1,223,140 award will support research to test Sanguinate's ability to boost collateralization and deliver oxygen to ischemic brain tissue, with...
This $853,135 federal Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under CFDA Program 93.853 Extramural Research Programs in the Neurosciences and Neurological Disorders, will support research to investigate the role of the complement C3a receptor in exacerbating acute post-ischemic brain injury and long-term neurological dysfunction following stroke. The key objectives are to: 1) Demonstrate that genetic inhibition of endothelial C3a receptor...
This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) federal grant program, provides $490,049 to Shearit LLC to evaluate the efficacy of the LAMIFLO drag-reducing polymer in reducing ischemic penumbra and core volumes, improving neurological recovery, and preventing hemorrhagic transformation in an acute ischemic stroke animal model. The one-year...
This $299,982 Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program aims to evaluate the safety and efficacy of Unandup, LLC's novel magnetic infusion platform for accelerating alteplase-based thrombolysis in an in vivo rat model of acute ischemic stroke. The technology is designed to more quickly deliver alteplase to obstructing blood clots,...
This federal Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, will support research to investigate the role of the skull bone marrow niche in post-stroke inflammation and recovery. The $798,848 award, effective March 1, 2025 through February 28, 2029, will enable The General Hospital Corporation (doing business as Massachusetts General...
The National Institute of Neurological Disorders and Stroke (NINDS) awarded a $294,729 Project Grant under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) to North Carolina State University. The funding will support the development of a versatile and compact telerobot with haptic feedback and physics-informed simulation to enhance the safety of neurovascular interventions for stroke treatment. The key products and services to be delivered include:...
This Project Grant award, provided by the National Institute of Neurological Disorders and Stroke (NINDS) under CFDA 93.853 Extramural Research Programs in the Neurosciences and Neurological Disorders, is focused on improving the understanding and treatment of stroke outcomes. The $539,597 award, granted on August 18, 2024, will support research to: 1) create a longitudinal dataset to evaluate the relationship between final infarct volume and clinical outcomes in patients with large vessel...
The National Institute of Neurological Disorders and Stroke (NINDS) awarded a $231,974 Project Grant (CFDA 93.853) to Celdara Medical, LLC to develop a neuroprotective therapy for acute ischemic stroke (AIS). The project aims to demonstrate the efficacy of Celdara's lead compound, CM-EA1, in preserving neurons in the ischemic penumbra and reducing disability in AIS patients. This work will involve preclinical studies in rodent models to evaluate the therapeutic potential of CM-EA1. Celdara...